Mesenchymal stem cells are a rescue approach for recovery of deteriorating kidney function.
OBJECTIVE
Stem cell (SC) therapy for chronic kidney disease (CKD) is urgently needed. The use of mesenchymal stem cells (MSC) is a possible new therapeutic modality. Our work aimed to isolate human MSC from adult bone marrow to improve kidney functions in CKD patients.


METHODS
In our study 30 patients with impaired kidney function were included, their ages ranged from 22 to 68 years. They included 10 inactive glomerulonephritis patients due to systemic lupus erythromatosus (SLE) (group I), 10 renal transplantation cases (group II) and 10 patients of other aetiologies as the control group. Fifty millilitres of bone marrow was aspirated from the iliac bone, for separation of MSC.


RESULTS
There was a highly statistically significant difference between both CD271 and CD29 before and after culture with increase of both markers at end of culture, P < 0.01. Finally 50-70 million MSC in 10 mL saline (0.7-1.0 × 10(6) MSC/kg body weight) were infused intravenously in two divided doses one week apart. There was a highly statistically significant difference between each of serum creatinine and creatinine clearance levels before and after MSC injection at 1, 3 and 6 months post-infusion with SLE cases showing a greater decline of their serum creatinine and elevation of mean creatinine clearance levels after injection than transplantation and control groups, P < 0.05.


CONCLUSIONS
Mesenchymal stem cells therapy is a potential therapeutic modality for early phases of CKD.
Departments of Clinical Pathology, Internal Medicine and Nephrology, Kasr El-Aini, Cairo University, Cairo, Egypt.
Mervat
M
El-Ansary
Gamal
G
Saadi
Samah M
SM
Abd El-Hamid
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D002469:Cell Separation; D002478:Cells, Cultured; D003404:Creatinine / Q000097:blood; D004534:Egypt; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D019012:Integrin beta1 / Q000378:metabolism; D007668:Kidney / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery*; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000276:immunology; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000378:metabolism; D010865:Pilot Projects; D017475:Receptors, Nerve Growth Factor / Q000378:metabolism; D020127:Recovery of Function; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000503:physiopathology / Q000601:surgery*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; D019012:Integrin beta1; C484065:NGFR protein, human; D009419:Nerve Tissue Proteins; D017475:Receptors, Nerve Growth Factor; D003404:Creatinine